Editorial Commentary: Combination Therapy for Pseudomonas aeruginosa Bacteremia: Where Do We Stand?

Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort

(2013) Carmen Peña et al.   CLINICAL INFECTIOUS DISEASES

β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: A meta-analysis

(2013) Konstantinos Z. Vardakas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Outcomes of Appropriate Empiric Combination versus Monotherapy for Pseudomonas aeruginosa Bacteremia

(2012) Dana R. Bowers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Influence of Multidrug Resistance and Appropriate Empirical Therapy on the 30-Day Mortality Rate of Pseudomonas aeruginosa Bacteremia

(2012) Laura Morata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical implications of β-lactam–aminoglycoside synergism: systematic review of randomised trials

(2011) Ronit Marcus et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis*

(2010) Anand Kumar et al.   CRITICAL CARE MEDICINE

Patients included in randomised controlled trials do not represent those seen in clinical practice: focus on antimicrobial agents

(2010) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS